Eledon Pharmaceuticals, Inc. — Director's Dealing 2017

Jul 5, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Novus Therapeutics, Inc. (NVUS)
CIK: 0001404281
Period of Report: 2017-06-30

Reporting Person: Morrison Jodie Pope (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-06-30	Stock Option (Right to Buy)	$5.85	A	18000	Acquired	2027-06-30	Common Stock (18000)	Direct

Footnotes

F1: This option represents a right to purchase a total of 18,000 shares of the Issuer's Common Stock. The shares will vest ratably each quarter over three years beginning on June 30, 2017.